Breast Cancer Therapy

Interferon and endostatin gene therapy outpace angiostatin in breast cancers

Published in Women's Health Weekly, August 1st, 2002

by Sonia Nichols, senior medical writer - According to doctors in Italy, interferon (IFN)-alpha or endostatin gene transfer hamper angiogenesis in murine models of human breast cancers and do so more effectively than angiostatin gene transfer.

The doctors work at the University of Padova in Italy, where they compared the effects of delivering angiostatin, endostatin, and IFN-alpha(1) with at least two human breast cancer cell lines (MCF7 and MDA-MB435) using Moloney leukemia virus-based retroviral vectors. Each type of transferred gene is known to convey angiogenic inhibition when delivered to cells in gene therapy.

Initially, S. Indraccolo and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-08-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry